What are you looking for?
Need help finding what you are looking for? Contact Us

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1409920

Cover Image

PUBLISHER: Greystone Research Associates | PRODUCT CODE: 1409920

Self-administered Injectable Immune Therapeutics, Products, Therapeutics, Markets & Strategies

PAGES: 250 Pages
DELIVERY TIME: 1-2 business days
PDF (Single User License)
USD 4850
PDF (Site License)
USD 6500
PDF (Enterprise License)
USD 9500

Add to Cart

Therapeutics is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for therapeutic biological drugs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Therapeutics for Refractory Conditions

Led by the proliferation of antibody-based drugs and candidates, biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. This shift away from small molecule drugs is creating opportunities for drug developers, device designers, packagers and - ultimately - pharmaceutical marketers.

Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones and other biological drugs also increase the need for safety and compliance.

What You Will Learn:

  • What are the market factors that define the therapeutic injectable immune disease market?
  • What are the major factors driving product development strategies within biologicals drug development organizations to 2028?
  • How does the availability of patient support resources influence prescribing decisions for immune drugs?
  • How important are drug developer-formulation technologist relationships in therapeutic market segments?
  • What is the current state of the global self-administered immune therapeutics development and manufacturing ecosystem?
  • What are the significant economic, technological, and regulatory factors affecting the selection criteria for self-administered immune therapeutics to 2028?

Table of Contents

The Market Opportunity

Delivery Market Dynamics

  • The Economics of Injectable Drugs
  • What's Driving the Growth in Injectable Devices?
  • Prefilled Syringes Proliferating
  • The Trend toward Self-Administration
  • Shifting Demographics
  • Innovation in Disposable Device Designs
  • Proliferation of Biological Drugs

Therapeutic Monoclonal Antibodies

  • Therapeutic Demand Drivers
  • Competitive Landscape
  • Risk Factors
  • Prefillable Commercial Devices for Biologicals
  • Manual Injection Autoinjectors
  • Automated Injection Autoinjectors
  • Disposable Autoinjectors
  • Autoinjector Product Summaries (21 Devices)

Wirelessly Enabled Autoinjectors (6 Devices)

  • Selected Product Specific Prefillable Autoinjectors (9 Devices)
  • Device Design Factors
  • Material Selection Issues
  • Part Counts and Device Cost
  • Safety Features
  • Needle Insertion Depth
  • Failsafe Activation
  • Dose Inspection/Injection Confirmation
  • Lyophilized Drugs/Reconstitution
  • Human Engineering/Ergonomics

Pen Injectors

  • Standardized Pen Platforms
  • Haselmeier
  • Becton Dickinson
  • Owen Mumford
  • Ypsomed
  • SHL Medical
  • Custom Pen Designs
  • Reusable Pens
  • Dual Chamber Pens

Commercial Pen Products (17 Products)

  • Reproductive Hormones
  • Commercial Pen Products
  • Follistim/Puregon Pen
  • Follistim Pen Product Summary
  • Gonal-f Rediject Pen Product Summary

Wearable Devices

  • Patch Pumps
  • Large Volume Wearable Devices
  • Wearables Product Analysis
  • Libertas (Becton Dickinson)
  • Patch Pump (Sensile Medical)
  • SmartDose (West Pharmaceuticals)
  • Neulasta OnPro Injector (Insulet/Amgen)
  • YpsoDose (Ypsomed)
  • Electronic Semi-disposable
  • E3D Patch Pump (Elcam)
  • Mechanical Disposable
  • enFuse (Enable Injections)
  • Captive Devices
  • sc2Wear Infusor (scPharmaceuticals)
  • PatchPump (SteadyMed)

Emerging Technology

  • Wireless Data
  • Key Therapeutic Sector Analysis
  • Anaphylaxis/Countermeasures
  • Autoimmune Diseases
  • Rheumatoid Arthritis
  • Psoriasis
  • Multiple Sclerosis
  • Emergency Medicine
  • Hepatitis
  • Hematopoietics
  • Hormones
  • Osteoporosis

Market Factors

  • Regulatory Issues
  • Device Branding
  • Patient Adherence and Ease of Use
  • Healthcare Economics
  • Biological Drug Product Factors
  • As-supplied Packaging
  • Formulation Factors
  • Biological Drug Delivery Ecosystem
  • Technology Factors
  • Competitive Landscape
Have a question?

Jeroen Van Heghe

Manager - EMEA



Christine Sirois

Manager - Americas


Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!